Bruker Corporation (NASDAQ: BRKR) experienced significant insider trading activity on November 6, 2023, when Director John Ornell sold 6,233 shares of the company’s stock. The shares were sold at an average price of $39.00, amounting to a total transaction value of $243,087. Following this sale, Ornell’s direct ownership in Bruker has decreased to 35,212 shares, which are now valued at approximately $1,373,268.
The sale represents a notable 15.04% reduction in Ornell’s stake in the company. This transaction was publicly disclosed through a filing with the U.S. Securities and Exchange Commission (SEC), which can be accessed for further details.
Bruker Stock Performance and Financial Overview
On the same day, shares of Bruker opened at $42.49. The company currently boasts a market capitalization of $6.46 billion, with a price-to-earnings (P/E) ratio of 81.71 and a price-to-earnings-growth (PEG) ratio of 5.31. Bruker’s beta stands at 1.26, indicating moderate volatility in stock performance.
In terms of financial health, Bruker has a debt-to-equity ratio of 1.31, a current ratio of 1.61, and a quick ratio of 0.70. Over the past year, the stock has fluctuated significantly, reaching a low of $28.53 and a high of $64.64. The company’s 50-day simple moving average is $35.59, while the 200-day moving average is $37.14.
Bruker recently reported its earnings results for the quarter ending November 3, 2023. The company announced earnings per share (EPS) of $0.45, surpassing analysts’ consensus estimates of $0.33 by $0.12. The firm reported revenues of $860.50 million, exceeding predictions of $847.40 million. Despite these positive results, Bruker’s revenue reflects a slight decline of 0.5% year-over-year, down from $0.60 EPS during the same quarter the previous year. Looking ahead, Bruker has provided guidance for its fiscal year 2025, projecting an EPS between $1.850 and $1.900.
Analyst Ratings and Institutional Investments
Recent analyst reports have shown varying opinions on Bruker’s stock. Wells Fargo & Company lowered their target price from $50.00 to $48.00 while maintaining an “overweight” rating. Cowen reaffirmed a “hold” rating, and TD Cowen raised their target price from $40.00 to $42.00, also giving a “hold” rating. Conversely, Citigroup reduced their target from $40.00 to $38.00 and assigned a “neutral” rating. According to MarketBeat, five analysts currently rate the stock as a “Buy,” six as a “Hold,” and one as a “Sell,” resulting in an average target price of $48.30.
Institutional ownership remains robust, with hedge funds and other institutional investors holding approximately 79.52% of Bruker’s stock. Notable transactions include Orbis Allan Gray Ltd acquiring a new position valued at $192.735 million in the second quarter. AQR Capital Management LLC increased their holdings by 125.3%, now owning over 3.3 million shares valued at around $137.065 million. Other significant investors include Sculptor Capital LP, Brown Advisory Inc., and Vaughan Nelson Investment Management L.P., all of which have significantly bolstered their stakes in recent months.
Bruker Corporation, headquartered in the United States, specializes in the development and distribution of scientific instruments and diagnostic solutions. The organization operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
For continuous updates and analysis on Bruker and other related companies, interested individuals can subscribe to MarketBeat’s daily email newsletter.
